California-based leading bioelectronics company, Pulse Biosciences, Inc. (PLSE), recently announced the successful completion of its first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System, a significant medical milestone that follows the system’s clearance by the Food and Drug Administration (FDA).
Pulse Biosciences is known for developing and harnessing the novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology. The CellFX nsPFA Percutaneous Electrode System, a result of this state-of-the-art technology, was utilized in a pioneering procedure. This development symbolizes a major step forward in the biosciences medical industry and various clinical applications.
The recently completed procedure is the first in Pulse Biosciences Inc.’s pilot program to implement the CellFX nsPFA Percutaneous Electrode System throughout the United States. The successful pilot program follows the March 2024 U.S. FDA 510(k) clearance, which authorized the use of the system in the ablation, a therapeutic process of removing tissue, of soft tissue in both percutaneous and intraoperative.
The Company’s announcement signifies a considerable move in leveraging its CellFX nsPFA technology to push the boundaries of what’s achievable in tissue ablation. The FDA 510(k) clearance is a testament of approval indicating the safety and effectiveness of the technology.
Pulse Biosciences remains at the forefront of revolutionizing bioelectronic medicine, focusing on the use of electrical pulses for tissue and cell therapies. The successful U.S. procedure with the CellFX system is a progressive stage in the company’s commitment to propelling technologies that can drastically enhance clinical outcomes.
Comments